Care Rail

← Medical · All 20 for Diabetes mellitus

Taiwan

Diabetes mellitus · Metabolic / renal

High ambulatory volume; global budgets constrain growth. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via NHI single payer.

Rank in this country#8
Share of deaths3.7%
Master rank#9
System quality rank#12

Access & coverage

NHI single payer

NHI single payer with smart-card claims; low waiting

Treatment

  • SGLT2/GLP-1 access is a major cross-country difference
  • Metformin / newer agents (SGLT2, GLP-1) where funded
  • Insulin pathways; dialysis / transplant for ESRD
  • Complication screening (eyes, feet, kidneys)

Prevention

  • Obesity / diabetes screening in primary care
  • CKD screening in diabetes and hypertension
  • School / workplace nutrition environments (weak but present)

Lifestyle

  • Calorie balance, diet quality, walking / resistance training
  • Glucose and BP self-management education
  • Sodium and protein guidance in CKD

What stands out here

Same broad metabolic / renal toolkit as peers — differences are coverage rules, wait times, prices, and follow-through.

vs master: +0.4 percentage points vs Top 20 average share.